Clinical Trials on Bardet-Biedl Syndrome 12 in Canada

Total 5 results

Rhythm Pharmaceuticals, Inc.

Completed

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

Bardet Biedl Syndrome (BBS) | Alström Syndrome (AS)

United States, United Kingdom, France, Canada, Puerto Rico, Spain
Rhythm Pharmaceuticals, Inc.

Completed

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Patients With Specific Gene Defects in the MC4R Pathway

Bardet-Biedl Syndrome | POMC Deficiency

Netherlands, United States, Germany, Canada, Puerto Rico, United Kingdom
Mansoura University

Completed

Diaphragm Thickness by Ultrasonography in Neurological Disorders

Myasthenia Gravis | Guillain-Barre Syndrome

Egypt
University of British Columbia
Centers for Disease Control and Prevention

Recruiting

Genomics and COVID-19 Vaccine Adverse Events

Vaccine Adverse Reaction

Canada
Erasmus Medical Center

Active, not recruiting

International Guillain-Barré Syndrome Outcome Study (IGOS)

Guillain-Barré Syndrome | Miller Fisher Syndrome

United States, Netherlands, United Kingdom, Bangladesh, Australia, Denmark, China, France, Germany, Spain, Argentina, Italy, Puerto Rico, South Africa, Belgium, Switzerland, Canada, Greece, Japan, Malaysia, Taiwan

3

Subscribe